PEGylation

We continue to apply this technology to a broad range of therapies, such as the PEGylated version of SN38, which has shown very encouraging results in preclinical studies.” — Hong Zhao Ph.D., Director, Organic and Medicinal Chemistry. Enzon is dedicated to developing innovative therapies through a variety of advanced technologies. Enzon’s proprietary PEGylation technology is a proven means of enabling or enhancing the performance of pharmaceuticals with delivery limitations, through the chemical attachment of polyethylene glycol or PEG via a linker. Advantages of PEGylation include increased efficacy, reduced toxicity, increased stability, and enhanced solubility. Click here to learn more about Enzon’s PEGylation technologies. Enzon has also developed Customized Linker TechnologyTM, which utilizes linkers designed to release the native molecule at a controlled rate. Enzon is also developing eight innovative RNA antagonists based on the locked Nucleic Acid® (LNA) Technology. Click here to learn more about this technology.